New
SM
Clara Fargo
EBMT Clinical Research Quality Assurance Coordinator
I have finalised the demo for the ICH-GCP E6 R3 refresher course. Overall, I liked the content and the interface. I also want to thank Whitehall Train...
Medical Writing of Periodic Benefit-Risk Evaluation Report (PBRER) Course & Certification
Intermediate
Watch Preview
4.7
★★★★★
97% Recommended
2 hours
31 active users
3 points
Watch Preview
Your Study Basket
Medical Writing of Periodic Benefit-Risk Evaluation Report (PBRER)
| Total | |
VAT is levied as per your country’s applicable rules and rates at checkout
Save more with a monthly or annual plan that includes this course
Secure Payment Service
Rest assured we use secure processes to protect your payment.
Secured by:
About
The Medical Writing of Periodic Benefit-Risk Evaluation Report (PBRER) Course & Certification is designed to provide a comprehensive understanding of the preparation, structure, and regulatory requirements of PBRERs in pharmacovigilance. The course focuses on evaluating the benefit–risk profile of medicinal products throughout their lifecycle in compliance with global regulatory standards.
This course covers PBRER structure, data collection and integration, benefit–risk evaluation, signal detection, regulatory expectations, and ICH E2C (R2) guidelines. It also emphasizes medical writing standards, quality review processes, documentation practices, and inspection readiness. Upon successful completion, learners receive a certification demonstrating competency in PBRER medical writing.
Who Should Enrol ?:
- Pharmacovigilance Professionals
- Medical Writers and Regulatory Writers
- Drug Safety and Risk Management Teams
- Clinical Research Professionals
- Regulatory Affairs Professionals
- Quality Assurance and Compliance Teams
- Pharmaceutical and Biotechnology Employees
- Life Science, Pharmacy, Nursing, and Medical Graduates
What you will learn
Understand the fundamentals of Periodic Benefit-Risk Evaluation Reports (PBRERs), including their purpose in ongoing drug safety monitoring and regulatory compliance.
Learn the standard structure and writing format of PBRERs, including key content components, data interpretation, and benefit-risk assessment.
Gain knowledge of how to develop clear conclusions and manage appendices while ensuring accuracy, consistency, and regulatory alignment.
Develop an understanding of quality control processes, SOP requirements, and regional regulatory variations in PBRER preparation and submission.
Course Syllabus
- What Is a PBRER?
- The Transition from PSUR to PBRER
- PSUR vs. PBRER: Key Differences
- ICH E2C(R2) Guideline: The Foundation
- Global Regulatory Framework for PBRER
- The International Birth Date (IBD): Timing PBRER Cycles
- Data Lock Point (DLP): Practical Considerations
- Stakeholder Responsibilities in PBRER Production
- The PBRER Multidisciplinary Team
- PBRER Reporting Schedule and Timelines
- PBRER vs. DSUR: Complementary Documents
- Clinical Trial Registries and PBRER
- The 20 Mandatory Sections of the PBRER
- The Modular Structure: Design and Purpose
- Reference Safety Information (RSI) and CCSI
- The 'Listedness' Concept: Listed vs. Unlisted ADRs
- MedDRA: Mandatory Terminology for Safety Data
- Technical Standards: FHIR and Modern Data Interchange
- PBRER-DSUR Content Sharing Framework
- Technical Format Requirements for PBRER Submission
- Fixed-Dose Combinations (FDCs): Special Considerations
- Sections 1–4: Regulatory Foundations
- Writing Section 1: Introduction
- Writing Section 2: Worldwide Marketing Authorization Status
- Section 5: Estimated Exposure and Use Patterns
- Exposure Calculation Methods: Post-Marketing
- Section 6: Data in Summary Tabulations
- Sections 7–14: Synthesizing Global Evidence
- Writing Section 7: Clinical Trial Summaries
- Sections 8 & 9: Non-interventional and Other Trials
- Sections 10 & 11: Non-clinical Data and Literature
- Sections 12 & 14: Other Reports and Late-Breaking Information
- Section 13: Lack of Efficacy in Controlled Clinical Trials
- Signal Management: The PBRER's Analytical Core
- Section 15: Overview of Signals — Typical Tabular Format
- Section 16: Signal and Risk Evaluation — Writing Guidance
- Crafting High-Quality Signal Narratives (Section 16)
- Sections 17–20: The Final Synthesis of Benefit and Risk
- Section 17: Benefit Evaluation
- Key Dimensions for the Benefit Narrative (Section 17)
- Section 18: Integrated Benefit-Risk Analysis — The Critical Section
- Integrated Benefit-Risk Assessment Framework
- Writing the Integrated Benefit-Risk Narrative
- Section 19: Conclusions and Actions
- Section 20: Appendices to the PBRER
- IPD Sharing Statements: Growing Regulatory Expectation
- Quality Control (QC) in PBRER Preparation
- Audit Readiness Checklist for PBRER Submission
- Site-Level Implementation and SOPs
- Global Variations in PBRER Requirements
- EU-Specific Requirements: The EURD List
- Final Synthesis: The Art and Science of PBRER Medical Writing
- PBRER Writing: Professional Development Pathways
Course Benefits
Fully compliant
This course describes the compliance requirements for the reporting of adverse events relating to medical devices. Learners also receive 4 Continual Professional Development (CPD) Points, accredited by The Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. These can be used to count towards the distance learning element of any scheme that comes under the umbrella of The Academy of Medical Royal Colleges or any other scheme for which there is mutual recognition.
Certified
All learners who pass the final exam receive a uniquely numbered, personal certificate to demonstrate their subject knowledge. Since the questions are picked randomly from a database, re-sitting the exam doesn’t mean taking the same questions again and again.
Affordable
Our cost-effective prices represent excellent value. You can easily pay up to ten-times more for face-to-face training. We can also offer generous group discounts on larger purchases.
Time-saving
Our new administration system makes it incredibly quick and simple to allocate licences to multiple learners. Learners save time too by choosing when and where they complete the training. Our reporting tools make it easy for administrators to check the progress of learners and identify areas for future training.
Reliable and trustworthy
This course was written by Steve Jolley, a recognised expert in International drug and device vigilance. You will stay up to date with any international legislative changes in device vigilance as our training courses are constantly monitored, reviewed and updated (last updated in May 2018). Steve Jolley is a Cambridge University graduate with 25 years’ experience in drug & device safety & vigilance, who specializes in global safety compliance, business process improvement and signal detection. He is the Chairperson of the DIA Clinical Safety and Pharmacovigilance steering committee for North America and has worked with over 80 clients in the US, Europe and Japan. He is a featured speaker with the FDA and MHRA at DIA conferences and webinars on drug safety topics including auditing and signaling.)
Our Certified Customers
Learner Rating & Reviews
4.7
★★★★★★
Average Rating
536 global ratings
★★★★★
87.0%
★★★★★
5.0%
★★★★★
3.0%
★★★★★
3.0%
★★★★★
2.0%
